Principaux documents

Voir toute la documentation

J4649

JNJ-10198409

Name: JNJ-10198409
Brand: SIGMA

≥98% (HPLC), solid

Synonyme(s) :

3-Fluoro-N-(6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine, N-(3-fluorophenyl)-2,4-dihydro-6,7-dimethoxy-Indeno[1,2-c]pyrazol-3-amine, RWJ 540973

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :

C₁₈H₁₆FN₃O₂

Numéro CAS:

627518-40-5

Poids moléculaire :

325.34

UNSPSC Code:

51111800

PubChem Substance ID:

329815736

NACRES:

NA.77

Assay:

≥98% (HPLC)

Form:

solid

Quality level:

100

Service technique

Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.

Laissez-nous vous aider

Propriétés

Quality Level

100

assay

≥98% (HPLC)

form

solid

color

off-white

solubility

DMSO: >10 mg/mL, H₂O: <2 mg/mL

originator

Johnson & Johnson

storage temp.

−20°C

SMILES string

COc1cc2Cc3c(Nc4cccc(F)c4)n[nH]c3-c2cc1OC

InChI

1S/C18H16FN3O2/c1-23-15-7-10-6-14-17(13(10)9-16(15)24-2)21-22-18(14)20-12-5-3-4-11(19)8-12/h3-5,7-9H,6H2,1-2H3,(H2,20,21,22)

InChI key

ZDNURMVOKAERHZ-UHFFFAOYSA-N

Description

Biochem/physiol Actions

JNJ-10198409 is a potent ATP-competitive inhibitor of Platelet-Derived Growth Factor receptor tyrosine kinase (PDGF-RTK) with both antiangiogenicand a directtumor cell antiproliferative activity. It is selective for PDGF-β kinase with IC₅₀ values of 4.2 nM for PDGF-β and 45 nM for PDGF-α kinase.

JNJ-10198409 is an ATP-competitive Platelet-Derived Growth Factor Receptor-beta (PDGFR-β) inhibitor.

Features and Benefits

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the PAF Receptor and PDGFR pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

wgk

WGK 3

Classe de stockage

11 - Combustible Solids

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

037K46201

037K4620

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis.

Michael R D'Andrea et al.

Molecular cancer therapeutics, 4(8), 1198-1204 (2005-08-12)

With the advent of agents directed against specific molecular targets in drug discovery, it has become imperative to show a compound's cellular impact on the intended biomolecule in vivo. The objective of the present study was to determine if we

(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.

Chih Y Ho et al.

Journal of medicinal chemistry, 48(26), 8163-8173 (2005-12-22)

A series of (6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines has been optimized to preserve both potent kinase inhibition activity against the angiogenesis target, the receptor tyrosine kinase of Platelet-Derived Growth Factor-BB (PDGF-BB), and to improve the broad tumor cell antiproliferative activity of these compounds. This